# LACTOBACILLUS FERMENT LYSATE (lactobacillus-ferment-lysate) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/lactobacillus-ferment-lysate
- **Standard INCI**: `LACTOBACILLUS FERMENT LYSATE`
- **KR MFDS Standard Name**: `락토바실러스발효용해물`
- **CAS No.**: `N/A`
- **EC / EINECS No.**: `N/A`
- **Origin**: `ferment`
- **Functions**: 피부컨디셔닝제
- **Molecular Formula / MW**: `—` (— g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 락토바실러스발효용해물 |
| KR (Former Names) | — |
| EU (CosIng 1223/2009) | LACTOBACILLUS FERMENT LYSATE |
| US (PCPC / MoCRA INCI) | LACTOBACILLUS FERMENT LYSATE |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | 乳酸杆菌发酵溶胞产物 |
| JP (JCIA / MHLW QD) | LACTOBACILLUS FERMENT LYSATE  |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `none`
- **EU (1223/2009)**: `none`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `allowed` (Entry: `5676`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`



## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- Listed within general cosmetic GMP safety thresholds.

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 4.5 – 7.5
- **Max Process Temp**: ≤ 70°C
- **Synergy Pairings**: —
- **Incompatibilities**: —

## 5. Academic Monograph
Lactobacillus Ferment Lysate is a lysate of the product obtained by fermentation of Lactobacillus.

## 6. Linked PubMed Literature
- [PMID: 35421680] Lactobacillus and intestinal diseases: Mechanisms of action and clinical applications — *Microbiol Res* (2022)
- [PMID: 37662007] Lactobacillus reuteri in digestive system diseases: focus on clinical trials and mechanisms — *Front Cell Infect Microbiol* (2023)
- [PMID: 34881196] Contribution of Lactobacillus iners to Vaginal Health and Diseases: A Systematic Review — *Front Cell Infect Microbiol* (2021)
- [PMID: 35068121] Approach to probiotics in pediatrics: the role of Lactobacillus rhamnosus GG — *Arch Argent Pediatr* (2022)
- [PMID: 39102225] Bifidobacterium and Lactobacillus Probiotics and Gut Dysbiosis in Preterm Infants: The PRIMAL Randomized Clinical Trial — *JAMA Pediatr* (2024)
- [PMID: 37575226] Orally administrated Lactobacillus gasseri TM13 and Lactobacillus crispatus LG55 can restore the vaginal health of patients recovering from bacterial vaginosis — *Front Immunol* (2023)